Ultra-rare TP53 and KRAS variants predict survival in ICI-treated solid tumours.

Clemente-Suárez VJ, Olivares R, Yáñez-Sepúlveda R, Guzmán-Muñóz E, Rodríguez AM

Open source

DOI
10.1007/s12094-026-04319-3
Published
2026 Sep
Container
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s12094-026-04319-3,
  title = {Ultra-rare TP53 and KRAS variants predict survival in ICI-treated solid tumours.},
  author = {Clemente-Suárez VJ and Olivares R and Yáñez-Sepúlveda R and Guzmán-Muñóz E and Rodríguez AM},
  year = {2026},
  journal = {Clinical \& translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico},
  doi = {10.1007/s12094-026-04319-3},
  url = {https://doi.org/10.1007/s12094-026-04319-3}
}

RIS

TY  - JOUR
TI  - Ultra-rare TP53 and KRAS variants predict survival in ICI-treated solid tumours.
AU  - Clemente-Suárez VJ
AU  - Olivares R
AU  - Yáñez-Sepúlveda R
AU  - Guzmán-Muñóz E
AU  - Rodríguez AM
PY  - 2026
JO  - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
DO  - 10.1007/s12094-026-04319-3
UR  - https://doi.org/10.1007/s12094-026-04319-3
ER  - 

APA

VJ, C., R, O., R, Y., E, G., & AM, R. (2026). Ultra-rare TP53 and KRAS variants predict survival in ICI-treated solid tumours.. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. https://doi.org/10.1007/s12094-026-04319-3

Source records